KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) EBT Margin (2023 - 2025)

Biocryst Pharmaceuticals' EBT Margin history spans 9 years, with the latest figure at 35030.65% for Q4 2025.

  • For Q4 2025, EBT Margin rose 3505041.0% year-over-year to 35030.65%; the TTM value through Dec 2025 reached 57.01%, up 7631.0%, while the annual FY2025 figure was 30.56%, 4986.0% up from the prior year.
  • EBT Margin reached 35030.65% in Q4 2025 per BCRX's latest filing, up from 7.61% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 35030.65% in Q4 2025 to a low of 52.41% in Q4 2023.
  • Average EBT Margin over 3 years is 3878.88%, with a median of 11.43% recorded in 2024.
  • The largest YoY upside for EBT Margin was 3505041bps in 2025 against a maximum downside of 1541bps in 2025.
  • A 3-year view of EBT Margin shows it stood at 52.41% in 2023, then skyrocketed by 62bps to 19.76% in 2024, then soared by 177381bps to 35030.65% in 2025.
  • Per Business Quant, the three most recent readings for BCRX's EBT Margin are 35030.65% (Q4 2025), 7.61% (Q3 2025), and 3.97% (Q2 2025).